Bright Minds Biosciences Inc. Common Stock (DRUG) is a publicly traded Healthcare sector company. As of November 2, 2026, DRUG trades at $20.98 with a market cap of $542.33M and a P/E ratio of 0.00. DRUG moved -55.23% today. Year to date, DRUG is -34.12%; over the trailing twelve months it is +0.94%. Its 52-week range spans $23.18 to $123.75. Analyst consensus is strong buy with an average price target of $165.25. Rallies surfaces DRUG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
FDA partial hold on BMB-101 trial; Bright Minds plans to seek clarification: The FDA placed a partial clinical hold on Bright Minds Biosciences’ planned US Phase 2 BMB-101 trial, citing mouse toxicity findings and insufficient data to support pediatric enrollment. The company plans to seek clarification and update the study based on FDA recommendations; it said other ongoing trials are unaffected.
| Metric | Value |
|---|---|
| Price | $20.98 |
| Market Cap | $542.33M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $123.75 |
| 52-Week Low | $23.18 |
| Volume | 224.12K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover DRUG: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $165.25.